



Overview of COVID-19 Vaccine

August 12, 2021

Housekeeping

- **How to Ask Questions**

- Click on the  icon found at the bottom part of your screen
- A box will open where you can type in questions, comments, indicate sound problems, etc.
- Use this throughout the webinar to ask questions


- **Slides & Recording**

- This webinar is being recorded and a link as well as slides will be emailed out through our listserv as well as posted on our website at: www.michigan.gov/COVIDvaccineprovider

Topics Covered

- Enrollment
- Storage and Handling
- Clinical Guidance
- Vaccine Status
- Fact Check
- Resources


COVID-19 Vaccine Provider Enrollment



Becoming a COVID-19 Vaccine Provider

- Must be enrolled in both the Michigan Care Improvement Registry (MCIR) and CDC's COVID-19 Vaccination Program
- **Who can enroll?** Any health care provider – including those from private practices and larger health systems. Urgent need for providers who serve children to enroll
- **When to enroll?** Now! Pediatric providers do not need to wait for FDA authorization to enroll. Enrolling now will ensure you are ready to administer vaccines quickly after authorization
- **Why enroll?** Enrollment is required to receive vaccines to administer. Patients are more likely to trust getting vaccinated at their doctor's office

COVID-19 Vaccine Provider Guidance and Educational Resources



This webpage will house materials to support COVID-19 Vaccine Providers in successful implementation of the COVID-19 Vaccination Program. Be sure to "bookmark" this page and check back frequently for updates!

GENERAL COVID-19 VACCINE RESOURCES

[Increasing Access to Vaccine Opportunities: Recommendations for Health Care Providers - Updated 6/18/21](#)

[COVID-19 Vaccines During Hospital Stays and Medical Appointments - Updated 6/14/21](#)

[COVID-19 Vaccination Clinic Preparation Checklist & Resource Toolkit - Updated 5/28/21](#)

[ACIP Recommendations for COVID-19 Vaccine](#)

[Interim Clinical Considerations for COVID-19 Vaccine](#)

[CDC COVID-19 Vaccine Resources for Healthcare Professionals](#)

- Vaccine administration, storage and handling, reporting, and patient education for each specific vaccine

[COVID-19 Vaccine Training Module](#)

- Self-paced module with certificate of completion (no CE)
- MDHHS strongly recommends that all COVID-19 Vaccine Providers complete this training.

[CDC HCP Vaccine Administration Resource Library](#)

CONTENT-SPECIFIC COVID-19 RESOURCES

[Webinars](#)

- [Upcoming Noontime Knowledge: TBD](#)

[Education Corner](#)

[Enrollment](#)

[Redistribution](#)

[Vaccine Billing and Vaccine Code Sets](#)

MDHHS / ADULT & CHILDREN'S SERVICES / CHILDREN & FAMILIES / IMMUNIZATION INFO FOR FAMILIES & PROVIDERS

COVID-19 Vaccine Provider Enrollment

Enrollment

- [Three Steps to participate in COVID-19 Vaccination Program](#)
- [Enrollment Checklist & Resource List](#)
- [CDC COVID-19 Vaccination Program FAQ](#)
- [SAMPLE_Section A Provider Agreement CDC COVID-19](#)
- [CDC COVID-19 Provider Requirement and Legal Agreement](#)
- [CDC Supplemental Redistribution form](#)
- [COVID-19 Vaccine Provider Guidance & Education](#)
- [VIDEO TUTORIALS](#)
 - [Tutorial 1: CDC COVID 19 Provider Agreement Section A](#)
 - [Tutorial 2: CMO and CEO Signatures](#)
- [Questions on Provider Enrollment: Email \[MDHHS-COVIDVaccineProviders@michigan.gov\]\(mailto:MDHHS-COVIDVaccineProviders@michigan.gov\)](#)
- **IMPORTANT:** For any enrolled provider wishing to transfer or receive doses from another site, you must review the [Redistribution page](#) and submit a [Redistribution Agreement](#) *prior to* any vaccine being redistributed.

Email: MDHHS-COVIDVaccineProviders@michigan.gov

www.michigan.gov/covidvaccineprovider



CDC COVID-19 Vaccination Frequently Asked Questions for Providers

How does an Organization participate in the CDC COVID-19 Vaccination Program?

Health Care Professionals who wish to administer the COVID-19 vaccine must be enrolled in the Michigan Care Improvement Registry (MCIR).

Once enrolled, the Corporate Organization must complete the [Vaccination Program Provider Agreement](#). When submitted, a confirmation email will be sent, and there will be a link to sign the agreement.

What if the Provider is not in the Michigan Care Improvement Registry?

Not every health care provider uses MCIR, but in order to administer COVID-19 vaccines providers must register with MCIR.

To begin registration in MCIR, Providers need to complete a registration form then needs to be sent the [MCIR Regional Office Staff](#).

Once your site is registered, MCIR Training can be arranged with the [Office Staff](#).



COVID-19 Provider Enrollment & Resource Center

Enrollment Steps:

Medical Providers seeking to enroll and participate with the State of Michigan CDC COVID-19 Vaccination Program.

1. **Complete a current [MCIR Provider Usage Agreement*](#)**, (if not already a current MCIR provider required for COVID immunizing provider application processing.
2. **Complete Part 1 of Enrollment** visit [Registration CDC COVID-19 Vaccination Program Provider Form](#).
3. **Complete Part 2 of Enrollment** directly in the MCIR system. Log in via [MILogin](#) to the MCIR system with your credentials to complete CDC COVID-19 Vaccine Site Provider Registration. You will need your Corporate/Organization CMO License number to complete this form.
4. **Approved** COVID-19 providers will receive an 'Congratulations' email from the MDHHS COVID-19 Immunization Provider Registration Processing Team with next steps and resource information. This approval does not guarantee your site will receive vaccine if you are not an enrolled and registered MDHHS CDC COVID-19 provider. A separate communication is sent when your site receives vaccine.
5. **Follow up** with questions regarding your enrollment please connect via email MDHHS-COVIDVaccineProviders@michigan.gov

Enrollment Application Requirements

- Organization Site & Affiliate Location Site(s) Information
- MCIR Site ID – [How to Find your MCIR Site ID](#)
- Chief Medical Officer & Chief Executive Officer, (fiduciary) License Information & Signatures
- Site Immunizing Provider (MD, DO, NP, PA, RPh) License Information
- Site Vaccine Storage Unit & Current Storage Capacity
- Site Vaccine Coordinator Contact Information, & Site Vaccine Delivery Times
- Site Provider Type and General Patient Demographic Information

Vaccine Storage & Handling, Administration & Redistribution Resources

Connect with your [Local Health Department](#) contact(s) regarding vaccine administration, vaccine storage & handling or redistribution concerns. Also, visit [MDHHS COVID-19 Provider Guidance Educational Resources](#).

MCIR Transaction, Documentation and Training Guidance

Connect with your [Regional MCIR Office](#) and visit our [MCIR Immunizing Provider webpage](#) or the [COVID-19 Immunizing Provider webpage](#) regarding site administrator, MCIR dose documentation, inventory adjustment and inventory education and training resources.



3 Steps for Health Care Professionals to participate in the CDC COVID-19 Vaccination Program

1. Are you enrolled in Michigan Care Improvement Registry (MCIR)?

If yes → Skip to Step 2
If no → Start at A:

A: All vaccine providers must be enrolled in MCIR. To enroll complete the [MCIR Provider Site Usage Agreement Fillable Form](#) and email or fax the form to your [MCIR Regional Office](#). Once approved, access MCIR through [MILOGIN](#). Access the [MILOGIN tip sheet](#) if needed.

B: Do you know your MCIR Site ID number?
If yes → Skip to Step 3
If no → Go To B:

Look up your [MCIR Site ID](#)

2. Start the [CDC COVID-19 Vaccination Program Provider Agreement](#).


The individual completing the Program Provider Agreement will be receiving all email regarding vaccines from the CDC and VaccineFinder. When submitted, a confirmation email will be sent, and the CMO and CEO will receive a link to sign the agreement.

3. Log into MCIR (through [MILOGIN](#)) to complete [CDC COVID-19 Vaccine Site Provider Registration](#).

The Corporate/Organization CMO License number will be needed to complete registration

If you have any questions, please email:
MDHHS-COVIDVaccineProviders@michigan.gov

COVID-19 Vaccine Storage & Handling



How Does
COVID-19
Vaccine Storage
and Handling
Make You Feel?

A word cloud of terms related to COVID-19 vaccine storage and handling. The words are arranged in a circular pattern and include: Shocks, Hours, Temperature, Transport, Excursion, Unpunctured, Drops, Cumulative, Punctured, Days, Diluent, Exposure, Reconstituted, UltraCold, Logger, Refrigerator, Freezer, Digital, Data, Light, 36°F, Thawed, Time, Vials, 2.8°C, 2°C, and 46°F.

CONTENT-SPECIFIC COVID-19 RESOURCES

Webinars

- **Upcoming Noontime Knowledge: TBD**

Education Corner

Enrollment

Redistribution


Vaccine Billing and Vaccine Code Sets

Product-Specific Information & EUAs

Pfizer

Moderna

Janssen (Johnson & Johnson)



EUA Fact Sheets

- **EUA Fact Sheet for Healthcare Professionals - UPDATED 6/25/21**
- **EUA Fact Sheet for Recipients - UPDATED 6/25/21**

- **Important:** Print and provide the above EUA Fact Sheet to each COVID-19 vaccine recipient/caregiver in Michigan.
- This version includes the information statement about the MCIR (as indicated in Michigan VISs). Per state law, patients/parents must be informed about MCIR.
- Translations
 - Arabic Updated 6/25/21
 - Cherokee Updated 6/25/21
 - Chinese-Simplified
 - Chinese-Traditional
 - Chuukese
 - French
 - German
 - Haitian-Creole
 - Hmong
 - Italian
 - Japanese
 - Marshallese
 - Polish
 - Somali
 - Spanish - Updated 6/25/21

DOSAGE AND ADMINISTRATION

Storage and Handling

During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

Do not refreeze thawed vials.

Frozen Vials Prior to Use

Cartons of Pfizer-BioNTech COVID-19 Vaccine Multiple Dose Vials arrive in thermal containers with dry ice. Once received, remove the vial cartons immediately from the thermal container and preferably store in an ultra-low temperature freezer between -80°C to -60°C (-112°F to -76°F) until the expiry date printed on the label. Alternatively, vials may be stored at -25°C to -15°C (-13°F to 5°F) for up to 2 weeks. Vials must be kept frozen and protected from light until ready to use. Vials stored at -25°C to -15°C (-13°F to 5°F) for up to 2 weeks may be returned one time to the recommended storage condition of -80°C to -60°C (-112°F to -76°F). Total cumulative time the vials are stored at -25°C to -15°C (-13°F to 5°F) should be tracked and should not exceed 2 weeks.

If an ultra-low temperature freezer is not available, the thermal container in which the Pfizer-BioNTech COVID-19 Vaccine arrives may be used as temporary storage when consistently re-filled to the top of the container with dry ice. Refer to the re-icing guidelines packed in the original thermal container for instructions regarding the use of the thermal container for temporary storage. The thermal container maintains a temperature range of -90°C to -60°C (-130°F to -76°F). Storage of the vials between -96°C to -60°C (-141°F to -76°F) is not considered an excursion from the recommended storage condition.

Transportation of Frozen Vials

If local redistribution is needed and full cartons containing vials cannot be transported at -90°C to -60°C (-130°F to -76°F), vials may be transported at -25°C to -15°C (-13°F to 5°F). Any hours used for transport at -25°C to -15°C (-13°F to 5°F) count against the 2-week limit for storage at -25°C to -15°C (-13°F to 5°F). Frozen vials transported at -25°C to -15°C (-13°F to 5°F) may be returned one time to the recommended storage condition of -80°C to -60°C (-112°F to -76°F).

Thawed Vials Before Dilution

Thawed Under Refrigeration


Thaw and then store undiluted vials in the refrigerator [2°C to 8°C (35°F to 46°F)] 95 vials may take up to 2 or 3 hours, whereas a fewer number of vials will thaw

EUA Fact Sheets (Healthcare Professionals)

www.michigan.gov/covidvaccineprovider

CDC Storage and Handling Toolkit

The Vaccine Storage and Handling Toolkit has been updated with an addendum to address proper storage, handling, transport, and emergency handling of COVID-19 vaccines.



<https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf>

COVID-19

Vaccine (Pfizer-BioNTech)

- » Vaccine may be stored until the expiration date, available. Contact the manufacturer to determine [CDC's expiration date tracking tool](#) to document
- » Protect vaccine from light.

Thermal Shipping Container

Store between -80° C and -60° C (-112° F and -76° F)

- » CDC recommends considering using the thermal shipping container
- » Use the Controlant TMD, included with the thermal shipping container
- » Keep the vaccine vials in the tray, with vaccine vials upright
- » Using proper PPE,* add dry ice pellets (10 mm to the Controlant TMD.
- » Open the container no more than two times per shipment
- » Protect vaccine from light.

Freezer

Store between -25°C and -15°C (-13°F to 5°F) for up to 2 weeks

- » If storing with routinely recommended vaccines, use the tighter temperature range
- » Vaccine stored in the freezer may be transferred to a refrigerator
- » Store vaccine in the tray.
- » Protect vaccine from light.
- » Use CDC's Pfizer [beyond-use date \(BUD\) labels](#) to determine BUD

Refrigerator

Store between 2° C and 8° C (36° F and 46° F) for up to 5 days

- » Once thawed, vaccine cannot be refrozen.
- » Vaccine can be stored for up to 120 hours (5 days)
- » After 120 hours (5 days), contact the manufacturer for guidance
- » Vaccine does not need to be protected from light
- » Use CDC's Pfizer [beyond-use date \(BUD\) labels](#) to determine BUD

Store diluent at room temperature following manufacturer's instructions

Temperature Monitoring: Use the Controlant Temperature Monitoring Device, to monitor the temperature.

- Ensure the contact information for your order (in Vtrac) is current
- Identify up to 4 contacts to receive e-mails and text alerts
- Review DAILY e-mails on the status of the container. Contact the manufacturer if you do not receive an e-mail. An Excel file summarizing all temperature data for at least 5 days will be delivered with the shipment.

*Dry ice will be delivered for the first 5 days of storage.

COVID-19

Vaccine (Pfizer-BioNTech)

Product Name: Pfizer-BioNTech COVID-19 Vaccine

Manufacturer Website: www.cvdvaccine.com

Manufacturer Phone Number: 1-877-829-2619 (1-877-VAX-CO19)

CDC Clinical Guidance for Pfizer-BioNTech COVID-19 Vaccine: www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html

Vaccine Temperature Ranges:

- Ultra-cold: -80° C and -60° C (-112° F and -76° F)
- Frozen: -25° C and -15° C (-13° F to 5° F) for up to 2 weeks
- Refrigerated: 2° C and 8° C (36° F and 46° F) for up to five days (120 hours)

Vaccine Storage Unit(s):

- Ultra-cold freezer
- Freezer for up to two weeks
- Thermal shipping container (if using, CDC recommends providers consider using for temporary storage only)
- Refrigerator for up to five days (120 hours)

Temperature Monitoring Device: For accurate temperature monitoring, use a digital data logger (DDL).

- **Ultra-cold freezer:** Use a DDL with an air-probe or a probe designed specifically for ultra-cold temperatures.
- **Freezer and refrigerator:** Use a DDL with a detachable probe that best reflects vaccine temperatures (e.g., probe buffered with glycol, glass beads, and or Teflon®).
- **Thermal shipping container:** Use the Controlant temperature monitoring device (TMD) included with the thermal shipping container.

Delivery:

- Vaccine arrives at a temperature between -80° C and -60° C (-112° F and -76° F) in a thermal shipping container with dry ice to maintain proper temperatures. Each shipping container holds up to five trays. Each carton/tray contains 195 multidose vials (1170 doses).
- Dry ice requires special handling and PPE. See the "Special Considerations" section below for more information.
- Each shipping container has a Controlant TMD that should be disabled following manufacturer's guidance.
- Ancillary supply kits will be delivered separately from the vaccine and include diluent and equipment needed to mix and administer the vaccine.

Storage Information: Vaccine can be stored in an ultra-cold freezer, thermal shipping container, freezer, or refrigerator following routine storage and handling best practices. Individual guidance for each storage unit is as follows:

Ultra-Cold Freezer

Store between -80° C and -60° C (-112° F and -76° F).

- » Pfizer will send an e-mail notification that vaccine has not experienced a temperature excursion during shipping and can be used. Once received, keep the vaccine vials in the tray and place the box in the storage unit.

- Temperature Range(s)
- Storage Unit(s)
- Temperature Monitoring Device
- Delivery
- Transport
- Preparation & Administration
- Special Considerations

CDC Storage and Handling Toolkit COVID-19 Vaccine Addendum

<https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf>

COVID-19 Vaccination

Clinical Resources for Each COVID-19 Vaccine

Find information for COVID-19 vaccination administration, storage and handling, reporting, and patient education for each specific vaccine

Product Information by U.S. Vaccine



ACIP
Recommendations



Storage and
Handling



General Vaccine
Administration



Training and
Education

Thermal Shipping Container

CDC recommends providers consider using the significant support to store vaccine at proper procedures for regular maintenance.

Use the Controlant temperature monitoring device included with the thermal shipping container to monitor the temperature.

- Review contact information.
 - If the contact for your order (inVTrckS) is will NOT be notified in the event of a temporary excursion. Contact your jurisdiction's immunization program for assistance.
 - If your contact is valid and you are not receiving or cannot load email hyperlinks, refer to the troubleshooting (https://ln.controlant.com/onsitemonitoring).
 - Identify up to 4 contacts to receive e-mails on the container's temperature status.
- Review **DAILY** e-mails on the status of the container.
- Click the link in daily e-mails to access and download all temperature data. Save the Excel file and temperature data for at least 3 years.
- Save the return shipping label provided in your container at delivery. Use the shipping label to return shipping container with the Controlant TM.

Ultra-Cold Freezer

Before mixing, the vaccine may be stored in an ultra-cold freezer at -80°C and -60°C (-112°F and -76°F).

- Store vaccine vials upright in the tray or box.
- Protect from light.
- Vaccine may be stored until the expiration date.

Freezer

Before mixing, the vaccine may be stored in a freezer that replaces the manufacturer's expiration date. This extends up to 2 weeks.

- These temperatures are within the appropriate range for routinely recommended vaccines, BUT the range for this vaccine is tighter.
- If storing the vaccine in a freezer with routinely recommended vaccines, carefully adjust the freezer temperature to the correct temperature range for this vaccine.
- Monitor how long the vaccine has been in the freezer using CDC's beyond-use date label for COVID-19 vaccine.
- Store the vaccine in the tray or box.

*It is preferred to return the shipping container.

Basics

- Store vaccine in an ultra-cold freezer, thermal shipping container, freezer, or refrigerator. See guidance below for each storage unit.
- Follow the manufacturer's instructions for returning the thermal shipping container.
- Check and record storage unit temperatures each workday. See guidance below for each type of storage unit. Save storage records for 3 years, unless your jurisdiction requires a longer time period.

Deliveries

Vaccine

Use CDC's Delivery Checklist for Pfizer-BioNTech Vaccine when accepting a delivery and unpacking vaccine. When vaccine is delivered:

1. Open the thermal shipping container. Press the stop shipment button on the temperature monitoring device for 5 seconds.
2. The LED indicator light will change to a solid color and a temperature status report will be e-mailed to the person who ordered the vaccine.
3. Proceed based on the color of the LED indicator light:
 - No color or red:** Wait for the status report.
 - Green:** Unpack the vaccine.
4. Follow the manufacturer's guidance for unpacking the vaccine. Inspect the trays.
 - Do not open the vial trays or remove vials until ready to thaw/use the vaccine.
 - If storing the vaccine at ultra-cold temperatures, return the vaccine to frozen storage with the manufacturer's instructions.
5. If not using the thermal shipping container, return the thermal shipping container to the manufacturer's instructions.
 - Ensure ALL the vaccine has been returned to the manufacturer.

Dry Ice Safety

1. Dry ice is needed to maintain proper temperatures in the thermal shipping container.
2. Ensure staff has proper PPE and is trained to handle dry ice safely.
3. Do not use or store dry ice in coolers, refrigerators, environmental chambers, or rooms without ventilation. A leak in such areas can lead to depletion of oxygen in the atmosphere, which can result in asphyxiation.

Ancillary Supply Kit

- An ancillary supply kit will be delivered separately from the vaccine and includes:
- **Mixing supplies:** Diluent, needles, syringes, and sterile alcohol prep pads
 - Mixing supplies are packaged separately with a green identification label.
 - Do NOT use mixing supplies to administer vaccine.
 - **Administration supplies:** Needles, syringes, sterile alcohol prep pads, vaccination PPE.
 - Ancillary supply kits have been pre-packed with the number of doses ordered.



U.S. COVID-19 Vaccine Product Information

Find a suite of information and materials that are needed for each specific COVID-19 vaccine that cover administration, storage and handling, safety, and reporting.

Pfizer-BioNTech

Moderna

Janssen/J&J

Pre-vaccination Screening Form
Download pre-vaccination checklist in multiple languages.

[Arabic](#) | [English](#) | [French](#) | [Haitian Creole](#) | [Korean](#) | [Portuguese](#) | [Simplified Chinese](#) | [Spanish](#) | [Vietnamese](#)

CDC Pfizer-BioNTech COVID-19 Resource Page

<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>

Follow storage and handling best practices in the *Vaccine Storage and Handling Toolkit* (<https://www.cdc.gov/vaccines-handling-toolkit.pdf>), to maintain the integrity of the transporting vaccine.

Transport Pfizer-BioNTech COVID-19 Vaccine using a monitoring device in a:

- Thermal shipping container
- Portable ultra-cold freezer unit
- Portable freezer unit
- Portable refrigerator unit
- Container/packout qualified for refrigerated temperatures

Upon arrival at the clinic, place the vaccine in the storage unit available, keep the vaccine at the maintaining recommended temperature.

Temperature monitoring:

Record time and minimum/maximum temperatures:

- At the start of transport
- Whenever the transport container is opened
- When transport concludes

General Information

- Transport equal amounts of vaccine and personal protective equipment
- Vaccine vials may be transported in a cooler
- Transport thawed vaccine at refrigerated temperatures
 - Individual vials or partially filled vials
 - Vaccine stored at refrigerated temperatures
- Both punctured and unpunctured vials are acceptable
- CDC recommends transporting pre-drawn vaccine in syringes in the USP COVID-19 Vaccine Handling Toolkit ([usp.org/covid-19/vaccine-handling](https://www.usp.org/covid-19/vaccine-handling))



Vaccine that has not been mixed has specific beyond-use dates for frozen and refrigerated storage. Use these labels to ensure beyond-use dates are followed.

Storing Vaccine in the Freezer

Pfizer-BioNTech COVID-19 Vaccine may be stored in the freezer between -25°C and -15°C (-13°F and 5°F) for up to 2 weeks.

- Remove the vaccine from ultra-cold temperature storage.
- Complete the information on the freezer storage label and attach it to the container or resealable plastic bag holding the vaccine vials.
- Once labeled, store the vaccine vials in the freezer between -25°C and -15°C (-13°F and 5°F) for up to 2 weeks.
- If the 2-week deadline is met, move any remaining vials to refrigerated storage for an additional 1 month (31 days).
- Update the beyond-use date labels to reflect the new BUD time frame.
- Keep vials removed from ultra-cold storage at the same time together.

Pfizer-BioNTech COVID-19 Vaccine

Store vaccine in the FREEZER between -25°C and -15°C (-13°F to 5°F) for up to 2 weeks.

Lot number(s): _____

Today's date: ____/____/____ Time: _____

USE BY*

Date: ____/____/____ Time: _____

*If the 2-week deadline is met, move any remaining vials to refrigerated storage for an additional 31 days. Use a refrigerator beyond-use date (BUD) label to reflect the new BUD time frame. Use a refrigerator beyond-use date (BUD) label to reflect the new BUD time frame.

Name: _____

Storing Vaccine in the Refrigerator

Pfizer-BioNTech COVID-19 Vaccine can be stored in the refrigerator between 2°C and 8°C (36°F and 46°F) for up to 1 month (31 days).

- Remove vaccine vials from ultra-cold or frozen temperature storage.
- Complete the information on the refrigerator storage label and attach it to the container or resealable plastic bag holding the vaccine vials.
- Once labeled, store the vaccine vials in the refrigerator between 2°C and 8°C (36°F and 46°F) for up to 1 month (31 days).
- As the 1 month (31 days) deadline approaches, contact the manufacturer for guidance if you will not be able to use the vaccine.
- Do NOT refreeze the vaccine.

Pfizer-BioNTech COVID-19 Vaccine

Store vaccine between 2°C and 8°C (36°F and 46°F) for up to 31 days.

Lot number(s): _____

Today's date: ____/____/____ **USE BY*** Date: ____/____/____

*As the 31 day deadline approaches, contact the manufacturer for guidance if you will not be able to use the vaccine.

Vaccine may be transported for 12 cumulative hours.

Transport date:			
Time in transport:			
Time remaining:			

Name: _____



Temperature Log
when Transporting Vaccine at Refrigerated Temperatures



When transporting refrigerated vaccines, use:

- A portable refrigerator or vaccine storage container qualified to maintain temperatures between 2°C and 8°C (36°F and 46°F).
- A digital data logger (DDL) with a thermal buffer and external temperature display (preferred). Place the probe as close as possible to the vaccine.
- This temperature log to document temperatures and how long the vaccine is in the portable storage container.

Temperature monitoring and transport time frames

- Most DDLs display minimum/maximum (min/max) temperatures.*
- Record the time and min/max temperatures:
 - At the start of transport
 - Every time the portable storage container is opened
 - When transport is completed
- The total time for transport alone or transport plus clinic workday should be a maximum of 8 hours.†
- Beyond-use date/time (BUD), if applicable, are included in transport time. For example, if the vaccine may be stored at refrigerated temperature for 120 hours, transport is included in this time frame.

! If the temperature is out of range, TAKE ACTION!

1. Do NOT discard the vaccine.
2. Label the vaccine "Do Not Use."
3. Complete the Vaccine Troubleshooting Record.
4. Contact the manufacturer to determine under what conditions (refrigerated) to store the vaccine as quickly as possible.

Today's date: _____ Transport start time: _____ Transport end time: _____

Provider name: _____ Facility name: _____ PIN number: _____

Temperatures measured in (circle one): Celsius Fahrenheit

Time																				
Staff initials																				
Min/max temperatures																				

Temperatures lower than 2°C (36°F) and higher than 8°C (46°F) are out of range.† Complete a Vaccine Troubleshooting Record. Contact the manufacturer and your immunization program.

- After packing the vaccine, open the portable storage container only when necessary.
 - If using a company or personal vehicle, transport vaccines inside the passenger compartment (not in the trunk or bed of a truck, which may be too hot or too cold).
 - Avoid leaving the portable storage container in direct sunlight or unattended.
 - If needed, transport diluents with their corresponding vaccines to ensure there are equal amounts of vaccines and diluents. Follow the manufacturer's guidance for specific temperature requirements for diluents.
 - Save this record for 3 years, unless your state/local jurisdiction requires a longer time period. See CDC's *Vaccine Storage and Handling Toolkit* for additional guidance.
 - Refer to CDC's *Vaccine Storage and Handling Toolkit* for additional guidance when transporting vaccines.
- * If the DDL does not measure min/max temperatures, check and record temperatures hourly.
† Follow the manufacturer's guidance if it differs from this time frame.

COVID-19
Quick Reference
Healthcare Prof

COVID-19 Vaccine
Quick Reference Guide for
Healthcare Professionals



The table below provides basic information on the proper storage, preparation, and administration of the currently authorized COVID-19 vaccine products in the United States. For additional information and detailed clinical guidance go to the manufacturer's and CDC's webpages listed.


		Pfizer	Moderna	Janssen	
VACCINE ADMINISTRATION	Route	Intramuscular	Intramuscular	Intramuscular	
	Site	Deltoid	Deltoid	Deltoid	
	Thawing Frozen Vaccine	Between 2°C and 8°C (36°F and 46°F) Do NOT freeze	Between 2°C and 8°C (36°F and 46°F) Do NOT freeze	Between 2°C and 8°C (36°F and 46°F) Do NOT freeze	
	Mixing Vaccine	Mix vaccine with sodium chloride normal saline	Mix vaccine with sodium chloride normal saline	Mix vaccine with sodium chloride normal saline	
	Contraindications/Precautions	<ul style="list-style-type: none"> Severe allergic reaction to any component of the vaccine History of Guillain-Barré syndrome History of severe allergic reaction to any component of the vaccine History of severe allergic reaction to gelatin or egg protein People currently receiving or who have received another COVID-19 vaccine People who are currently pregnant or breastfeeding People who are currently taking medications that may interact with the vaccine 	<ul style="list-style-type: none"> Severe allergic reaction to any component of the vaccine History of Guillain-Barré syndrome History of severe allergic reaction to any component of the vaccine History of severe allergic reaction to gelatin or egg protein People currently receiving or who have received another COVID-19 vaccine People who are currently pregnant or breastfeeding People who are currently taking medications that may interact with the vaccine 	<ul style="list-style-type: none"> Severe allergic reaction to any component of the vaccine History of Guillain-Barré syndrome History of severe allergic reaction to any component of the vaccine History of severe allergic reaction to gelatin or egg protein People currently receiving or who have received another COVID-19 vaccine People who are currently pregnant or breastfeeding People who are currently taking medications that may interact with the vaccine 	
	Post-Vaccination Observation	30 minutes	15 minutes	15 minutes	
	Most common adverse events	Injection site pain, redness, swelling	Injection site pain, redness, swelling	Injection site pain, redness, swelling	
	GENERAL	EUA	www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine	www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine	www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19/janssen-covid-19-vaccine
		CDC Vaccine Information	www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html	www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html	www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html
		Manufacturer Contact information	Website: www.cvdvaccine.com Medical information: 800-438-1985 Customer service: 800-879-3477	Website: www.modernatx.com Medical Information: 866-663-3762	Website: www.vaxcheck.jnj.com Medical information: 1-800-565-4008
STORAGE & HANDLING	How supplied	Multidose vial: 6 doses	Multidose vial: Maximum of 15 doses	Multidose vial: 5 doses	
	Diluent	0.9% sodium chloride (preservative-free, normal saline) provided in the ancillary kit. Do NOT use other diluent.	None	None	
	Storage Temperatures: Before Puncture	Between: -80°C and -60°C (-112°F and -76°F) until the expiration date Between: -25°C and -15°C (-13°F and 5°F) for up to 2 weeks Between: 2°C and 8°C (36°F and 46°F) for up to 1 month (31 days).	Between: -50°C and -15°C (-58°F and 5°F) until the expiration date Between: 2°C and 8°C (36°F and 46°F) for up to 30 days Between: 8°C and 25°C (46° and 77°F) for a total of 24 hours	Between: 2°C and 8°C (36°F and 46°F) until the expiration date.	
	Storage Temperatures: After puncture	Between: 2°C to 25°C (36°F to 77°F) for up to 6 hours. Discard any unused vaccine after 6 hours.	Between: 2°C and 25°C (36°F and 77°F) for up to 12 hours. Discard any unused vaccine after 12 hours.	Between: 2°C and 8°C (36°F and 46°F) for up to 6 hours. Between: 9°C and 25°C (47°F and 77°F) for up to 2 hours. Discard any unused vaccine after these time frames.	
	Transport Temperatures: Before Puncture	Between: -80°C and -60°C (-112°F and -76°F) Between: -25°C and -15°C (-13°F and 5°F) Between: 2°C and 8°C (36°F and 46°F)	Between: -50°C and -15°C (-58°F and 5°F) Between: 2°C and 8°C (36°F and 46°F) for up to 12 cumulative hours.	Between: 2°C and 8°C (36°F and 46°F)	
	Transport Temperatures: After Puncture	Between: 2°C to 25°C (36°F to 77°F) for up to 6 hours.	Between: 2°C and 25°C (36°F and 77°F) for up to 12 hours.	Between: 2°C and 8°C (36°F and 46°F) for up to 6 hours	
	Type of Vaccine	mRNA	mRNA	Viral vector	
	Age Indications	12 years of age and older	18 years of age and older	18 years of age and older	
	Schedule	2-doses, separated by 21 days. Both doses must be Pfizer-BioNTech vaccine	2 doses, separated by 28 days. Both doses should be Moderna vaccine	1 dose only	

COVID-19 Quick Reference Guide

- How supplied
- Diluent
- Storage Temperatures
 - Before/after puncture
- Transport Temperatures
 - Before/after puncture

<https://www.cdc.gov/vaccines/covid-19/downloads/covid19-vaccine-quick-reference-guide-2pages.pdf>

Clinical Guidance



Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States



Interim considerations: [preparing for the potential management of anaphylaxis after COVID-19 vaccination](#)

Reference Materials

[Summary Document for Interim Clinical Considerations](#)

[Summary Document for Interim Clinical Considerations poster](#)

[COVID-19 Vaccine Administration Errors and Deviations](#)

[COVID-19 Vaccine Administration Errors and Deviations Poster](#)

Get Email Updates

To receive email updates about this page, enter your email address:

[What's this?](#)

Summary of recent changes (last updated August 6, 2021):

- Updated considerations for COVID-19 vaccination in people with a history of Guillain-Barré syndrome
- Updated information on vaccine administration errors and deviations in Appendix A (Table).

Key points

COVID-19 vaccination is recommended for everyone 12 years and older for the prevention of coronavirus disease 2019 (COVID-19) in the United States. The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of:

- [Pfizer-BioNTech COVID-19 vaccine](#) (in persons [aged 12–15 years](#) and [aged ≥16 years](#))
- [Moderna COVID-19 vaccine](#) (in persons aged ≥18 years)
- [Janssen \(Johnson & Johnson\) COVID-19 vaccine](#) (in persons aged ≥18 years)

These clinical considerations provide additional information to healthcare professionals and public health officials on use of COVID-19 vaccines.

On This Page

[Background](#)

[Vaccination of pregnant or lactating people](#)

[Authorized age groups](#)

[Vaccination of children and adolescents](#)

[Vaccine administration](#)

[Patient counseling](#)

[Interchangeability of COVID-19 vaccine products](#)

[Contraindications and precautions](#)

[People vaccinated outside the United States](#)

[Reporting of vaccine adverse events](#)

[Coadministration with other vaccines](#)

[Laboratory testing](#)

[Booster doses](#)

[Appendix A: Vaccine administration errors and deviations](#)

[COVID-19 vaccination and SARS-CoV-2 infection](#)

[Appendix B: Triage of people presenting for COVID-19 vaccination](#)

[Antiviral therapy and COVID-19 vaccination](#)

[Vaccinating people with a known COVID-19 exposure or during COVID-19 outbreaks](#)

[Appendix C: Ingredients included in COVID-19 vaccines](#)

[Considerations for vaccination of people with certain underlying medical conditions](#)

[Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following COVID-19 vaccination](#)

[Considerations for use of the Janssen COVID-19 vaccine in certain populations](#)

[References](#)

[Previous Updates](#)

CDC Interim Clinical Considerations for Use of COVID-19 Vaccines

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

People Vaccinated Outside the U.S.

- In some circumstances people who received a COVID-19 vaccine **not currently authorized in the United States** may be offered revaccination with an FDA-authorized vaccine:
 - COVID-19 vaccines not authorized by FDA but listed for emergency use by WHO
 - People who have received all recommended doses of a COVID-19 vaccine that is listed for emergency use by WHO **do not need** any additional doses with an FDA-authorized COVID-19 vaccine
 - People who have not received all the recommended doses of a COVID-19 vaccine listed for emergency use by WHO may be offered a complete, FDA-authorized COVID-19 vaccine series
 - COVID-19 vaccines neither authorized by FDA nor listed for emergency use by WHO
 - People who received all or some of the recommended doses of a COVID-19 vaccine that is neither authorized by FDA nor listed for emergency use by WHO may be offered a complete, FDA-authorized COVID-19 vaccine series
- The minimum interval between the last dose of a non-FDA authorized vaccine or a WHO-listed vaccine and an FDA-authorized COVID-19 vaccine is 28 days

Coadministration With Other Vaccines

- COVID-19 vaccines and other vaccines **may now be administered without regard to timing**
 - COVID-19 vaccines can be administered simultaneous with other vaccines on the same day, as well as within 14 days
- It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines
 - Consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines
- **If multiple vaccines are administered at a single visit, administer each injection in a different injection site.** For adolescents and adults, the deltoid muscle can be used for **more than one** intramuscular injection

Booster Doses

- The need and timing for COVID-19 booster doses have not been established
- No additional doses are recommended at this time
- Guidance may be updated as more information becomes available
- ACIP scheduled to meet Friday August 13 from 11a.m.-2p.m. (draft agenda-considerations for booster doses of COVID-19 vaccines)
 - No vote scheduled at this time

Considerations for Vaccination of People with Certain Underlying Medical Conditions

- *Myocarditis or pericarditis after receipt of the first dose of an mRNA COVID-19 vaccine series but before administration of the second dose*
 - **Until additional safety data are available, experts recommend that people who develop myocarditis or pericarditis after a first dose of an mRNA COVID-19 vaccine defer receiving the second dose**
- Administration of the second dose of an mRNA COVID-19 vaccine series can be considered in certain circumstances
- Clinicians should consult current clinical guidance for information on the evaluation and management of myocarditis
- *History of myocarditis or pericarditis prior to COVID-19 vaccination*
 - People who have a history of myocarditis or pericarditis unrelated to mRNA COVID-19 vaccination may receive any FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved
- CDC is continuing to investigate cases of myocarditis or pericarditis after mRNA COVID-19 vaccination; this guidance may be updated as new information is obtained

Considerations for Vaccination of People with Certain Underlying Medical Conditions

People with a history of Guillain-Barré syndrome

- Reports of adverse events following use of the Janssen COVID-19 vaccine under EUA suggest an increased risk of GBS during the 42 days following vaccination
- No increased risk of GBS has been identified with mRNA vaccines during use under EUA
- People with a history of GBS **can receive** any FDA-authorized COVID-19 vaccine
 - Given the possible association between the Janssen COVID-19 vaccine and an increased risk of GBS, a patient with a history of GBS and their clinical team should discuss the availability of mRNA COVID-19 vaccines to offer protection against COVID-19
- Any occurrence of GBS following COVID-19 vaccination should be reported to VAERS

Appendix A:

Vaccine Administration Errors and Deviations

- This appendix provides resources for preventing and reporting COVID-19 vaccine administration errors, as well as actions to take after an error has occurred


mRNA vaccines only (Pfizer-BioNTech and Moderna)	Intervals	<ul style="list-style-type: none"> Second dose administered fewer than 17 days (Pfizer-BioNTech) or fewer than 24 days (Moderna) after the first dose (i.e., administered earlier than the 4-day grace period) 	<ul style="list-style-type: none"> Do not repeat dose.
		<ul style="list-style-type: none"> Second dose administered more than 42 days after the first dose 	<ul style="list-style-type: none"> Do not repeat dose. This deviation from CDC guidance does not require VAERS reporting.
	Mixed series	<ul style="list-style-type: none"> Incorrect mRNA COVID-19 vaccine product administered for second dose in 2-dose series 	<ul style="list-style-type: none"> Do not repeat dose.⁵

Appendix B: Triage of People Presenting for COVID-19 Vaccination

Appendix B: Triage of people presenting for COVID-19 vaccination

CONTRAINDICATION TO VACCINATION	PRECAUTION TO VACCINATION	MAY PROCEED WITH VACCINATION
<p>History of the following:</p> <ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the vaccine† • Immediate allergic reaction* of any severity after a previous dose or known (diagnosed) allergy to a component of the vaccine† 	<p>Among people without a contraindication, a history of:</p> <ul style="list-style-type: none"> • Any immediate allergic reaction* to other vaccines or injectable therapies‡ <p>Note: people with a contraindication to mRNA COVID-19 vaccines have a precaution to Janssen COVID-19 vaccine, and vice versa. See footnote for additional information on additional measures to take in these people.#</p>	<p>Among people without a contraindication or precaution, a history of:</p> <ul style="list-style-type: none"> • Allergy to oral medications (including the oral equivalent of an injectable medication) • History of food, pet, insect, venom, environmental, latex, etc., allergies • Family history of allergies
<p>Actions:</p> <ul style="list-style-type: none"> • Do not vaccinate. • Consider referral to allergist-immunologist. • Consider other vaccine alternative.† 	<p>Actions:</p> <ul style="list-style-type: none"> • Risk assessment • Consider referral to allergist-immunologist • 30-minute observation period if vaccinated 	<p>Actions:</p> <ul style="list-style-type: none"> • 30-minute observation period: people with history of anaphylaxis (due to any cause) • 15-minute observation period: all other people

Vaccine Status



Submissions to the FDA-Pending

- Pfizer-BioNTech submitted application to the FDA for full approval of their COVID-19 vaccine for those 16 years and older on May 7, 2021
- Moderna submitted application to the FDA for full approval of their COVID-19 vaccine for those 18 years and older on June 1, 2021
- Moderna filed with the FDA for an EUA expansion to include adolescents 12-17 years of age on June 10, 2021


Pediatric Clinical Trials

- Those 11 years of age and younger remain ineligible for COVID-19 vaccine
- Clinical trials for children are important to determine the dose, safety, and immune response
- Currently there are five trials recruiting participants and three active trials that are not currently recruiting participants
 - 3 of the 5 recruiting are Pfizer, one is Moderna, and one including both vaccines
 - Looking at ages 6 months through 11 years
 - 6 months to less than 2 years
 - 2 years to less than 5 years
 - 5 years to less than 12 years

When Will Vaccine be Available for Children Under 12 Years of Age?

- COVID-19 vaccines for children are coming, but the studies are needed to provide important information to ensure safe and effective vaccination of this group
- Currently, it is anticipated that the first data in children younger than 12 years of age may be submitted for review later this year; hopefully, sometime in the fall, but only time will tell
- Because these children cannot be vaccinated, those between 2 and 11 years of age should mask when they are in situations with large numbers of people, particularly if they are indoors or in areas where viral transmission is high

Fact Check!



NO! Vaccine shedding is the term used to describe the release or discharge of any of the vaccine components in or outside of the body. Vaccine shedding can only occur when a vaccine contains a weakened version of the virus. None of the vaccines authorized for use in the United States contain a live virus.

<https://www.chop.edu/news/feature-article-viral-shedding-and-covid-19-what-can-and-can-t-happen>

Do any of the COVID-19 vaccines authorized for use in the United States shed or release any of their components?

Myth: COVID-19 Vaccines have caused 1,000s of deaths.

Chart Report About

[Access](#) [Help for Results](#) [Printing Tips](#) [Help with Exports](#)

Options To

ADVERSE are updated every Friday. Hence, results for the same query can change from week to week.
739 total events.

Vaccine	→ Events Reported ↑↓	← P
COVID19 (COVID19 (JANSSEN)) (1203)	557	
COVID19 (COVID19 (MODERNA)) (1201)	2,890	
COVID19 (COVID19 (PFIZER-BIONTECH)) (1200)	2,881	
COVID19 (COVID19 (UNKNOWN)) (1202)	28	
Total	6,356	
Total	6,356	


ort to VAERS does not mean that healthcare personnel or the vaccine caused or contributed to the adverse event (pos

[Top](#) [Options](#)


reports reports of adverse events and reactions that occur following vaccination. Healthcare providers, vaccine providers, and the public can submit reports to VAERS. While very important in monitoring vaccine safety, VAERS data cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports provide information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports to VAERS are unverified, which means they are subject to biases. This creates specific limitations on how the data can be used. Data from VAERS reports should always be interpreted with these limitations in mind.

Strengths of VAERS are that it is national in scope and can quickly provide an early warning of a safety problem with a vaccine. As part of CDC and FDA's multi-system approach to post-licensure vaccine safety monitoring, VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as "safety signals." If a safety signal is identified in VAERS, further studies can be done in safety systems such as the CDC's Vaccine Safety Datalink (VSD) and the National Immunization Safety Assessment (CISA) project. These systems do not have the same limitations as VAERS and can better assess health risks and possible connections between adverse events and a vaccine.

Resources



COVID-19 Vaccine Provider Guidance and Educational Resources



This webpage will house materials to support COVID-19 Vaccine Providers in successful implementation of the COVID-19 Vaccination Program. Be sure to "bookmark" this page and check back frequently for updates!

GENERAL COVID-19 VACCINE RESOURCES

[Increasing Access to Vaccine Opportunities: Recommendations for Health Care Providers](#) - Updated 6/18/21

[COVID-19 Vaccines During Hospital Stays and Medical Appointments](#) - Updated 6/14/21

[COVID-19 Vaccination Clinic Preparation Checklist & Resource Toolkit](#) - Updated 5/28/21

[ACIP Recommendations for COVID-19 Vaccine](#)

[Interim Clinical Considerations for COVID-19 Vaccine](#)

[CDC COVID-19 Vaccine Resources for Healthcare Professionals](#)

- Vaccine administration, storage and handling, reporting, and patient education for each specific vaccine

[COVID-19 Vaccine Training Module](#)

- Self-paced module with certificate of completion (no CE)
- MDHHS strongly recommends that all COVID-19 Vaccine Providers complete this training.

[CDC HCP Vaccine Administration Resource Library](#)

CONTENT-SPECIFIC COVID-19 RESOURCES

[Webinars](#)

- [Upcoming Noontime Knowledge: Thursday July 1, 2021 at 12:00 pm](#)

[Education Corner](#)

[Enrollment](#)

[Redistribution](#)

[Vaccine Billing and Vaccine Code Sets](#)

MDHHS COVID-19 Provider Guidance and Education Website

www.michigan.gov/covidvaccineprovider

Meeting Information

Committee Information +

Committee Members +

Apply for ACIP Membership

Work Groups +

Recommendations +

Evidence Based Recommendations +

Get Email Updates

To receive email updates about this page, enter your email address:

Email Address

[What's this?](#)

Submit

Related Links

[Vaccines & Immunizations](#)

[Immunization Schedules](#)

[VFC Resolutions](#)

[Vaccine Information Statements \(VISs\)](#)

ACIP Meeting Information

The ACIP holds three meetings each year at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia to review scientific data and vote on vaccine recommendations. Meetings are open to the public and available online via live webcast.

Meeting Registration

Public Comment

Upcoming Meetings

Meeting Materials

In order to attend the ACIP meeting, in person, at CDC's Clifton Road campus, ACIP attendees (participants and visitors) must register online. Registration is not necessary to listen to the meeting via phone or live meeting. For in-person attendance, the week prior to the meeting you will receive a placard for your vehicle (parking tag) and instructions for navigating the secure CDC environment to attend the ACIP meeting.

ACIP Meeting Registration

The June 18, 2021 COVID-19 meeting is being rescheduled due to the observation of the Juneteenth National Independence Day holiday. The discussion will be rescheduled to be included as part of the June 23-25 ACIP meeting.

No Registration is required for the June 23-25, 2021 ACIP Meeting.

Registration is NOT required to watch the live meeting webcast.

Rules of Conduct for ACIP Meetings

- An interested person who wishes to make an oral public comment during an ACIP meeting should submit a request with the Centers for Disease Control and Prevention (CDC) before the meeting according to the instructions in the Federal Register Notice. Those who have not submitted a request before the meeting will only have an opportunity to speak as time permits or at the discretion of the Chair.
- Audience members may not present comments or questions to the Committee unless recognized by the Chair.
- Attendees may be subject to security screening, such as presenting identification, passing through metal detectors, and inspection of briefcases, packages, and so on.
- Attendees at the meeting are asked to maintain order and not display behavior that is disruptive to the meeting.
- The ACIP Chair or Designated Federal Officer will note on the record any disruptive behavior and will ask the person to cease the behavior or else leave the meeting room.
- We ask that attendees not approach the ACIP table area before, during, or after the meeting without permission from a Designated Federal Officer/Executive Secretary.

<https://www.cdc.gov/vaccines/acip/meetings/index.html>

ACIP Meeting Webpage

- Meeting Agendas
- Meeting Minutes
- Live Meetings
- Presentation Slides

Thank You!

Next “Noontime Knowledge”
Update: August 26, 2021

Please watch your email for a
date, link, and topic!

Questions Email:
checcimms@michigan.gov

www.michigan.gov/COVIDvaccineprovider

